Boehringer Ingelheim

Release Summary

Boehringer Ingelheim today announced the initiation of a Phase II trial of afatinib (Giotrif®) plus pembrolizumab (Keytruda®) for patients with locally advanced or metastatic SqCC of the lung.

Boehringer Ingelheim